Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel
about
Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosisMitotoxicity in distal symmetrical sensory peripheral neuropathiesOlesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound.Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.Drug discovery and development for spinal muscular atrophy: lessons from screening approaches and future challenges for clinical development.Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.The response of spinal microglia to chemotherapy-evoked painful peripheral neuropathies is distinct from that evoked by traumatic nerve injuries.Protective role of olesoxime against wild-type α-synuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells.Terminal arbor degeneration--a novel lesion produced by the antineoplastic agent paclitaxel.Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy.Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat.Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel.Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin.LIGAND-RECEPTOR INTERACTIONS AND DRUG DESIGN.Olesoxime protects embryonic cortical neurons from camptothecin intoxication by a mechanism distinct from BDNF.Nerve growth factor alters microtubule targeting agent-induced neurotransmitter release but not MTA-induced neurite retraction in sensory neurons.Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase.Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin-μ.Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice.Emerging drugs for diabetic neuropathy.Chemotherapy induced peripheral neuropathic painMinimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives.Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation.The calpain-suppressing effects of olesoxime in Huntington's disease.Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis
P2860
Q24596378-2B188C28-0E74-4A84-9EB9-2D17704EC211Q28834071-DBF42DE8-FE72-4505-B33F-AC73A3F34244Q31135310-1CDA043E-3547-4F23-880D-45BD31FE03D8Q34056025-FE4A7B71-0EEA-4FB5-895F-057F01A5FF0EQ34172502-3DD00E20-CA66-42CA-9A9C-AE06CB7BA7A0Q34194773-5807E524-2DF5-4897-AEAD-89B18969377EQ34579481-86690C3F-965B-4DC6-8DA6-F7E89DBC741FQ34795775-A097580F-6C4C-4DF0-86CE-BBF4EC73CF35Q34917256-D00FBD13-FD7F-4A9D-81C9-45BEE7075065Q35449249-18DA5F52-6B37-4127-B859-46B9A64DBC29Q35613627-6E6237AD-092A-4525-9DAA-1F6CB21286A9Q35740234-BC5560E5-4920-4475-9DF2-C6D37C82DEA4Q35784775-01095ED3-890F-4A0A-A88D-4CA2F7D80B6FQ36395316-6E8C09ED-BCAE-473D-892E-6A016EA217BBQ36757014-FEE6A1BB-EAA9-4926-8505-C810B36D3EF3Q36884527-2C8C3EB0-5029-49C8-B0CD-E3D99676EDC1Q36909043-147186E2-E076-46E7-BAA3-B38D1EE60657Q36988206-3C415A5B-1583-4093-969E-1737EB7A7272Q37399781-DE68D0F6-6022-43D4-81EA-340D5D21521FQ37583394-AB946E37-31D1-4B78-9AB7-F5C533380216Q37783301-D07911F4-55E7-4165-901B-026A475723E0Q38237393-7CAC4227-FB06-4C70-ABF9-1591EA962620Q38522262-BCC9364B-8DFA-4C56-BF62-53970742A05BQ39014966-91169E00-FBF8-4711-8DD6-027C1930C03AQ39108634-2E7388CA-3445-48F0-825E-AC8B67F98F70Q40402039-B0854015-8BC0-46BE-A4AC-CC11E6F91E1FQ45290815-2425E3D3-0E92-40D3-B8D0-041B817DC5F0Q57666978-DC3E2A55-083B-4CAB-9384-FA47696BE304
P2860
Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Olesoxime (cholest-4-en-3-one, ...... otherapeutic agent, paclitaxel
@ast
Olesoxime (cholest-4-en-3-one, ...... otherapeutic agent, paclitaxel
@en
Olesoxime (cholest-4-en-3-one, ...... otherapeutic agent, paclitaxel
@nl
type
label
Olesoxime (cholest-4-en-3-one, ...... otherapeutic agent, paclitaxel
@ast
Olesoxime (cholest-4-en-3-one, ...... otherapeutic agent, paclitaxel
@en
Olesoxime (cholest-4-en-3-one, ...... otherapeutic agent, paclitaxel
@nl
prefLabel
Olesoxime (cholest-4-en-3-one, ...... otherapeutic agent, paclitaxel
@ast
Olesoxime (cholest-4-en-3-one, ...... otherapeutic agent, paclitaxel
@en
Olesoxime (cholest-4-en-3-one, ...... otherapeutic agent, paclitaxel
@nl
P2093
P2860
P3181
P1433
P1476
Olesoxime (cholest-4-en-3-one, ...... otherapeutic agent, paclitaxel
@en
P2093
Felix Y Zheng
Gary J Bennett
Rebecca M Pruss
Thierry Bordet
Wen Hua Xiao
P2860
P3181
P356
10.1016/J.PAIN.2009.09.006
P407
P577
2009-12-15T00:00:00Z